Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

doi:10.1001/jama.2021.21699

. 2022 Jan 4;327(1):80-82.

doi: 10.1001/jama.2021.21699.

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Marie Joelle Jabagi¹, Jérémie Botton¹, Marion Bertrand¹, Alain Weill¹, Paddy Farrington², Mahmoud Zureik¹, Rosemary Dray-Spira¹

Affiliations

¹ EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
² School of Mathematics and Statistics, the Open University, Milton Keynes, United Kingdom.

PMID: 34807248
PMCID: PMC8609457
DOI: 10.1001/jama.2021.21699

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Marie Joelle Jabagi et al. JAMA. 2022.

. 2022 Jan 4;327(1):80-82.

doi: 10.1001/jama.2021.21699.

Authors

Marie Joelle Jabagi¹, Jérémie Botton¹, Marion Bertrand¹, Alain Weill¹, Paddy Farrington², Mahmoud Zureik¹, Rosemary Dray-Spira¹

Affiliations

¹ EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
² School of Mathematics and Statistics, the Open University, Milton Keynes, United Kingdom.

PMID: 34807248
PMCID: PMC8609457
DOI: 10.1001/jama.2021.21699

Abstract

This population-based study evaluates the short-term risk of severe cardiovascular events among French residents aged 75 years or older after receipt of the BNT162b2 mRNA COVID-19 vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Cited by

Pulmonary embolism after SARS-CoV-2 vaccination.
Zethelius B, Attelind S, Westman G, Ljung R, Sundström A. Zethelius B, et al. Vaccine X. 2024 Oct 15;21:100571. doi: 10.1016/j.jvacx.2024.100571. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39474208 Free PMC article.
Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database.
Karam R, Iskandar K, Watfa M, Zeitoun A. Karam R, et al. BMC Public Health. 2024 Oct 21;24(1):2905. doi: 10.1186/s12889-024-20297-z. BMC Public Health. 2024. PMID: 39434043 Free PMC article.
BAYESIAN LEARNING OF COVID-19 VACCINE SAFETY WHILE INCORPORATING ADVERSE EVENTS ONTOLOGY.
Zhao B, Zhong Y, Kang J, Zhao L. Zhao B, et al. Ann Appl Stat. 2023 Dec;17(4):2887-2902. doi: 10.1214/23-aoas1743. Epub 2023 Oct 30. Ann Appl Stat. 2023. PMID: 39282096 Free PMC article.
Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.
Tran HNQ, Risk M, Nair GB, Zhao L. Tran HNQ, et al. NPJ Vaccines. 2024 Sep 13;9(1):166. doi: 10.1038/s41541-024-00960-7. NPJ Vaccines. 2024. PMID: 39271677 Free PMC article.
Patients With ST-Segment Elevation Myocardial Infarction and Cerebrovascular Accidents: Impact of COVID-19 Vaccination on Mortality.
Patel S, Ballout M, Khan S, Robinson S, Adams AM, Rynarzewska A, Delzell JE Jr. Patel S, et al. Cardiol Res. 2024 Aug;15(4):275-280. doi: 10.14740/cr1688. Epub 2024 Aug 20. Cardiol Res. 2024. PMID: 39205963 Free PMC article.

See all "Cited by" articles

References

1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
1. Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2009;10(1):3-16. doi:10.1093/biostatistics/kxn013 - DOI - PubMed
1. Barda N, Dagan N, Ben-Shlomo Y, et al. . Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475 - DOI - PMC - PubMed
1. Klein NP, Lewis N, Goddard K, et al. . Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed

[2] Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed

[3] Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2009;10(1):3-16. doi:10.1093/biostatistics/kxn013 - DOI - PubMed

[4] Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2009;10(1):3-16. doi:10.1093/biostatistics/kxn013 - DOI - PubMed

[5] Barda N, Dagan N, Ben-Shlomo Y, et al. . Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475 - DOI - PMC - PubMed

[6] Barda N, Dagan N, Ben-Shlomo Y, et al. . Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475 - DOI - PMC - PubMed

[7] Klein NP, Lewis N, Goddard K, et al. . Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072 - DOI - PMC - PubMed

[8] Klein NP, Lewis N, Goddard K, et al. . Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Affiliations

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical